Suzhou Ribo climbs on EU clinical trials application of RBD3133 for obesity

Suzhou Ribo Life Science

08/10/2026 06:16

** Shares of Suzhou Ribo Life Science 6938.HK climb 6.3% to HK$56.95, their biggest intraday pct gain since September 29 
** Company announces submission of Phase I clinical trial application for its INHBE-targeting siRNA product RBD3133 Injection for overweight and obesity as its therapeutic indication in EU
** The RBD3133 is the company's first candidate drug in the obesity therapeutic area  
** Since debut on January 9, Suzhou stock down 3.8% from the offer price of HK$57.97 each
** YTD, Hang Seng Biotech Index .HSBIO up 12.4%



 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))